Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

The Role of New Technologies in Myeloproliferative Neoplasms.

Palumbo GA, Stella S, Pennisi MS, Pirosa C, Fermo E, Fabris S, Cattaneo D, Iurlo A.

Front Oncol. 2019 Apr 26;9:321. doi: 10.3389/fonc.2019.00321. eCollection 2019. Review.

2.

Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients.

De Roeck L, Michaux L, Debackere K, Lierman E, Vandenberghe P, Devos T.

Hematology. 2018 Dec;23(10):785-792. doi: 10.1080/10245332.2018.1498182. Epub 2018 Jul 11.

PMID:
29993347
3.

In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1+ BCP-ALL.

Fiedler ERC, Bhutkar A, Lawler E, Besada R, Hemann MT.

Blood Adv. 2018 Jun 12;2(11):1229-1242. doi: 10.1182/bloodadvances.2017015610.

4.

Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.

Pichler R, Fritz J, Tulchiner G, Klinglmair G, Soleiman A, Horninger W, Klocker H, Heidegger I.

BJU Int. 2018 Jan;121(1):29-37. doi: 10.1111/bju.14019. Epub 2017 Oct 12.

5.

A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients.

Vezzalini M, Mafficini A, Tomasello L, Lorenzetto E, Moratti E, Fiorini Z, Holyoake TL, Pellicano F, Krampera M, Tecchio C, Yassin M, Al-Dewik N, Ismail MA, Al Sayab A, Monne M, Sorio C.

J Hematol Oncol. 2017 Jun 21;10(1):129. doi: 10.1186/s13045-017-0494-z.

6.

Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations.

Lekovic D, Gotic M, Skoda R, Beleslin-Cokic B, Milic N, Mitrovic-Ajtic O, Nienhold R, Sefer D, Suboticki T, Buac M, Markovic D, Diklic M, Cokic VP.

Ann Hematol. 2017 Mar;96(3):393-404. doi: 10.1007/s00277-016-2890-9. Epub 2016 Dec 6.

PMID:
27924369
7.

Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.

Gupta S, Li J, Kemeny G, Bitting RL, Beaver J, Somarelli JA, Ware KE, Gregory S, Armstrong AJ.

Clin Cancer Res. 2017 Mar 1;23(5):1346-1357. doi: 10.1158/1078-0432.CCR-16-1211. Epub 2016 Sep 6.

8.

BCL11A expression in acute phase chronic myeloid leukemia.

Yin J, Zhang F, Tao H, Ma X, Su G, Xie X, Xu Z, Zheng Y, Liu H, He C, Mao ZJ, Wang Z, Chang W, Gale RP, Wu D, Yin B.

Leuk Res. 2016 Aug;47:88-92. doi: 10.1016/j.leukres.2016.05.018. Epub 2016 May 24. Erratum in: Leuk Res. 2017 Jan;52:67.

PMID:
27285855
9.

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.

Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T.

Blood. 2016 Apr 28;127(17):2131-43. doi: 10.1182/blood-2015-11-681171. Epub 2016 Feb 10.

10.

Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.

Liang X, Liu X, Wang B, Zou F, Wang A, Qi S, Chen C, Zhao Z, Wang W, Qi Z, Lv F, Hu Z, Wang L, Zhang S, Liu Q, Liu J.

J Med Chem. 2016 Mar 10;59(5):1984-2004. doi: 10.1021/acs.jmedchem.5b01618. Epub 2016 Feb 5.

PMID:
26789553
11.

Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma.

Andrews MC, Turner N, Boyd J, Roberts AW, Grigg AP, Behren A, Cebon J.

Clin Cancer Res. 2015 Dec 1;21(23):5222-34. doi: 10.1158/1078-0432.CCR-15-0393. Epub 2015 Jul 22.

12.

The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.

Lin Y, Liu E, Sun Q, Ma J, Li Q, Cao Z, Wang J, Jia Y, Zhang H, Song Z, Ai X, Shi L, Feng X, Li C, Wang J, Ru K.

Am J Clin Pathol. 2015 Jul;144(1):165-71. doi: 10.1309/AJCPALP51XDIXDDV.

PMID:
26071474
13.

Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells.

Askmyr M, Ågerstam H, Lilljebjörn H, Hansen N, Karlsson C, von Palffy S, Landberg N, Högberg C, Lassen C, Rissler M, Richter J, Ehinger M, Järås M, Fioretos T.

Blood Cancer J. 2014 Dec 12;4:e269. doi: 10.1038/bcj.2014.89.

14.

Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer.

Sourbier C, Ricketts CJ, Matsumoto S, Crooks DR, Liao PJ, Mannes PZ, Yang Y, Wei MH, Srivastava G, Ghosh S, Chen V, Vocke CD, Merino M, Srinivasan R, Krishna MC, Mitchell JB, Pendergast AM, Rouault TA, Neckers L, Linehan WM.

Cancer Cell. 2014 Dec 8;26(6):840-850. doi: 10.1016/j.ccell.2014.10.005.

15.

MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens.

Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, Irizarry RA, Liu JS, Brown M, Liu XS.

Genome Biol. 2014;15(12):554.

16.

Pegasus: a comprehensive annotation and prediction tool for detection of driver gene fusions in cancer.

Abate F, Zairis S, Ficarra E, Acquaviva A, Wiggins CH, Frattini V, Lasorella A, Iavarone A, Inghirami G, Rabadan R.

BMC Syst Biol. 2014 Sep 4;8:97. doi: 10.1186/s12918-014-0097-z.

17.

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).

Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Harrison C, Hehlmann R, Hermouet S, Kiladjian JJ, Kröger N, Mesa R, Mc Mullin MF, Pardanani A, Passamonti F, Samuelsson J, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tognoni G, Barbui T.

Leukemia. 2015 Jan;29(1):20-6. doi: 10.1038/leu.2014.250. Epub 2014 Aug 25. Review.

PMID:
25151955
18.

Improved diagnosis of the transition to JAK2 (V⁶¹⁷F) homozygosity: the key feature for predicting the evolution of myeloproliferative neoplasms.

Gonzalez MS, De Brasi CD, Bianchini M, Gargallo P, Stanganelli C, Zalcberg I, Larripa IB.

PLoS One. 2014 Jan 27;9(1):e86401. doi: 10.1371/journal.pone.0086401. eCollection 2014.

19.

Dkk3 levels in patients with myeloproliferative neoplasms.

Medinger M, Muesser P, Girsberger S, Skoda R, Tzankov A, Buser A, Passweg J, Tsakiris DΑ.

Thromb Res. 2014 Feb;133(2):218-21. doi: 10.1016/j.thromres.2013.11.003. Epub 2013 Nov 14.

PMID:
24309205
20.

A CALM-derived nuclear export signal is essential for CALM-AF10-mediated leukemogenesis.

Conway AE, Scotland PB, Lavau CP, Wechsler DS.

Blood. 2013 Jun 6;121(23):4758-68. doi: 10.1182/blood-2012-06-435792. Epub 2013 Mar 13.

Supplemental Content

Loading ...
Support Center